Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | HTR5A | P47898 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16195090 | 0.86 | METAP2 (0.39) | SLC2A1HDAC1MMP1PRKD1 | |
| SCHEMBL3342454 | 0.86 | VCP (0.36) | SLC2A1HDAC1MMP1 | |
| SCHEMBL3050325 | 0.84 | HSD11B1 (0.33) | SLC2A1HDAC1MMP1HTR5A | |
| SCHEMBL3340389 | 0.84 | SLC2A1 (0.36) | SLC2A1HDAC1MMP1PRKD1 | |
| SCHEMBL3338262 | 0.81 | MRGPRX4 (0.35) | SLC2A1MMP1KDM1A | |
| Trifluoroacetic Acid SCHEMBL3337454 | 0.80 | SLC2A1 (0.55) | SLC2A1HDAC1HTR5A | |
| SCHEMBL3048636 | 0.78 | HSD11B1 (0.33) | — | |
| SCHEMBL3050607 | 0.78 | HSD11B1 (0.33) | SLC2A1 | |
| SCHEMBL3043808 | 0.78 | POLB (0.33) | — | |
| SCHEMBL3047256 | 0.77 | HSD11B1 (0.32) | SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | SLC2A1 2287/4885HDAC1 1478/4885MMP1 4810/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | SLC2A1 4173/4885HDAC1 2440/4885MMP1 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.